CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that data provided in a presentation entitled, “Antitumor activity of single small molecule agent targeting PI3K/mTor and HDAC,” were presented at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010, which is being held in Washington, DC April 17-21. The poster highlights data on the Company’s novel research compound CU-906, which is designed to inhibit HDAC and PI3K/mTOR targets simultaneously. This presentation was given during a poster session on April 20th by Rudi Bao, M.D., Ph.D., Curis’ Senior Director of Oncology.
